Copyright
©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Feb 28, 2005; 11(8): 1141-1148
Published online Feb 28, 2005. doi: 10.3748/wjg.v11.i8.1141
Published online Feb 28, 2005. doi: 10.3748/wjg.v11.i8.1141
Table 1 Experimental designs used in this study.
Group ID | Numberof animal | Treatment | Sacrificed time |
CCl4 | 15 | CCl4, 1.0 mg/(kg·d), IP 3 times a wk 0.25% CMC, 1 mL/(kg·d), PO 5 times a wk | 4, 8, 12 wk |
CCl4+ Sily | 15 | CCl4, 1.0 mg/(kg·d), IP 3 times a wk Silymarin, 50 mg/(kg·d), PO 5 times a wk | 4, 8, 12 wk |
Table 2 Histopathological findings of liver tissue in the CCl4- or CCl4 with silymarin-treated groups.
Group | 4 wk | 8wk | 12 wk | |||
Grade1 | Lesion | Grade | Lesion | Grade | Lesion | |
CCl4 | 2 | Mild fibrosis | 3 | Severe fibrosis | 4 | Cirrhosis |
CCl4+Sily | 0-1 | Mild fatty change | 1-2 | Mild fatty change and fibrosis | 2-3 | Severe fatty change and fibrosis |
- Citation: Jeong DH, Lee GP, Jeong WI, Do SH, Yang HJ, Yuan DW, Park HY, Kim KJ, Jeong KS. Alterations of mast cells and TGF-β1 on the silymarin treatment for CCl4-induced hepatic fibrosis. World J Gastroenterol 2005; 11(8): 1141-1148
- URL: https://www.wjgnet.com/1007-9327/full/v11/i8/1141.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i8.1141